title: Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
abstract: Rituximab has been used extensively in lymphoproliferative disorders. We evaluated the results of 64 consecutive patients treated between 2001 and 2004 at our institution. This included 54 males and 10 females. The median age was 54 years (range 17 to 85 years). One-fourth of patients were above 60 years. The histology was aggressive NHL in 35, indolent NHL in 22 and 7 cases were diagnosed as CLL. Among NHL, sixteen were in early stage (I/II) and the remaining forty-one were in advanced stage (III/IV) of disease. B symptoms were present in 47% of cases. A total of 33 were de novo cases and 31 were previously treated. Rituximab monotherapy was used in 17 cases. Rituximab was used in combination with chemotherapy in the other 47 cases. Infusional toxicity included anaphylaxis in one, hypotension in one and minor infusional reactions in four others. The patient who developed anaphylaxis required discontinuation of further Rituximab. Growth factors were used in 25 patients. Febrile neutropenia occurred in 19 patients. The overall RR (CR + PR) was 72%. One patient had stable disease and progressive disease was documented in 17 patients. A total of seven patients died, three due to progressive disease, three due to chemotherapy related toxicity and one due to an unrelated cause. We conclude that Rituximab is a valuable addition to the treatment armamentarium of lymphoproliferative disorders.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: G
authors.initials: G
authors.lastname: Biswas
authors.forename: P M
authors.initials: PM
authors.lastname: Parikh
authors.forename: R
authors.initials: R
authors.lastname: Nair
authors.forename: R
authors.initials: R
authors.lastname: Bhagwat
authors.forename: A
authors.initials: A
authors.lastname: Bakshi
authors.forename: K
authors.initials: K
authors.lastname: Prabhash
authors.forename: A
authors.initials: A
authors.lastname: Vora
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: V R
authors.initials: VR
authors.lastname: Pai
authors.forename: H
authors.initials: H
authors.lastname: Menon
authors.forename: P S R K
authors.initials: PS
authors.lastname: Sastry
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007194:India; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D000069283:Rituximab